Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Honig

Showing results (151-160 of 273) with videos related to

Pageof 28
Sort By:
Journal of Alzheimer'S Disease : JAD|June 20, 2018
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension StudyStephen P Salloway, Reisa Sperling, Nick C Fox, et al.
Alzheimer'S Research & Therapy|May 10, 2024
Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseLawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, et al.
Theranostics|August 8, 2024
Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mappingSua Bae, Keyu Liu, Antonios N Pouliopoulos, et al.
Medrxiv : the Preprint Server for Health Sciences|January 10, 2024
Transcranial Blood-Brain Barrier Opening in Alzheimer's Disease Patients Using a Portable Focused Ultrasound System with Real-Time 2-D Cavitation MappingSua Bae, Keyu Liu, Antonios N Pouliopoulos, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Basic Science and PathogenesisShyam Tamizharasu, David Garcia, Naomi Saito, et al.
Acta Neuropathologica Communications|June 29, 2023
The neuropathological landscape of Hispanic and non-Hispanic White decedents with Alzheimer diseaseRebeca Scalco, Naomi Saito, Laurel Beckett, et al.
Acta Neuropathologica Communications|August 18, 2014
Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severityLyndsey E Collins-Praino, Yitshak I Francis, Erica Y Griffith, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
The Journal of Prevention of Alzheimer'S Disease|March 19, 2025
Association of dietary fatty acids with longitudinal change in plasma-based biomarkers of Alzheimer's diseaseSerena S Hoost, Lawrence S Honig, Min Suk Kang, et al.
Acta Neuropathologica Communications|May 24, 2024
The neuropathological landscape of small vessel disease and Lewy pathology in a cohort of Hispanic and non-Hispanic White decedents with Alzheimer diseaseHsin-Pei Wang, Rebeca Scalco, Naomi Saito, et al.
Pageof 28

Showing results (151-160 of 273) with videos related to

Sort By:
Pageof 28
Journal of Alzheimer'S Disease : JAD|June 20, 2018
Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension StudyStephen P Salloway, Reisa Sperling, Nick C Fox, et al.
Alzheimer'S Research & Therapy|May 10, 2024
Updated safety results from phase 3 lecanemab study in early Alzheimer's diseaseLawrence S Honig, Marwan N Sabbagh, Christopher H van Dyck, et al.
Theranostics|August 8, 2024
Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mappingSua Bae, Keyu Liu, Antonios N Pouliopoulos, et al.
Medrxiv : the Preprint Server for Health Sciences|January 10, 2024
Transcranial Blood-Brain Barrier Opening in Alzheimer's Disease Patients Using a Portable Focused Ultrasound System with Real-Time 2-D Cavitation MappingSua Bae, Keyu Liu, Antonios N Pouliopoulos, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 25, 2025
Basic Science and PathogenesisShyam Tamizharasu, David Garcia, Naomi Saito, et al.
Acta Neuropathologica Communications|June 29, 2023
The neuropathological landscape of Hispanic and non-Hispanic White decedents with Alzheimer diseaseRebeca Scalco, Naomi Saito, Laurel Beckett, et al.
Acta Neuropathologica Communications|August 18, 2014
Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severityLyndsey E Collins-Praino, Yitshak I Francis, Erica Y Griffith, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
The Journal of Prevention of Alzheimer'S Disease|March 19, 2025
Association of dietary fatty acids with longitudinal change in plasma-based biomarkers of Alzheimer's diseaseSerena S Hoost, Lawrence S Honig, Min Suk Kang, et al.
Acta Neuropathologica Communications|May 24, 2024
The neuropathological landscape of small vessel disease and Lewy pathology in a cohort of Hispanic and non-Hispanic White decedents with Alzheimer diseaseHsin-Pei Wang, Rebeca Scalco, Naomi Saito, et al.
Pageof 28